- Home
- NYC vs SCNX Comparison
NYC vs SCNX Comparison
Compare NYC & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- SCNX
- Stock Information
- Founded
- NYC 2013
- SCNX 2010
- Country
- NYC United States
- SCNX United States
- Employees
- NYC N/A
- SCNX N/A
- Industry
- NYC Real Estate
- SCNX Other Pharmaceuticals
- Sector
- NYC Finance
- SCNX Health Care
- Exchange
- NYC Nasdaq
- SCNX Nasdaq
- Market Cap
- NYC 24.9M
- SCNX 21.2M
- IPO Year
- NYC N/A
- SCNX 2020
- Fundamental
- Price
- NYC $9.89
- SCNX $0.78
- Analyst Decision
- NYC
- SCNX
- Analyst Count
- NYC 0
- SCNX 0
- Target Price
- NYC N/A
- SCNX N/A
- AVG Volume (30 Days)
- NYC 7.6K
- SCNX 430.8K
- Earning Date
- NYC 11-11-2025
- SCNX 11-05-2025
- Dividend Yield
- NYC N/A
- SCNX N/A
- EPS Growth
- NYC N/A
- SCNX N/A
- EPS
- NYC N/A
- SCNX N/A
- Revenue
- NYC $54,865,000.00
- SCNX $128,202.00
- Revenue This Year
- NYC $8.40
- SCNX N/A
- Revenue Next Year
- NYC $1.62
- SCNX N/A
- P/E Ratio
- NYC N/A
- SCNX N/A
- Revenue Growth
- NYC N/A
- SCNX N/A
- 52 Week Low
- NYC $7.89
- SCNX $0.69
- 52 Week High
- NYC $16.30
- SCNX $9.55
- Technical
- Relative Strength Index (RSI)
- NYC 43.51
- SCNX 31.35
- Support Level
- NYC $9.46
- SCNX $0.81
- Resistance Level
- NYC $10.25
- SCNX $0.89
- Average True Range (ATR)
- NYC 0.64
- SCNX 0.05
- MACD
- NYC 0.09
- SCNX 0.02
- Stochastic Oscillator
- NYC 56.95
- SCNX 16.36
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.